BiotechTube
CureLab Oncology

CureLab Oncology

Boston, United States· Est.
curelaboncology.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15.5M

Overview

CureLab Oncology is a private, clinical-stage biotech developing Elenagen, a plasmid DNA therapy encoding the p62/SQSTM1 gene, designed to modulate the tumor microenvironment and enhance anti-cancer immunity. The company has successfully completed an international Phase I/IIa trial demonstrating safety and preliminary efficacy, and is now advancing into Phase II studies both outside and within the US. With a seasoned leadership team, CureLab is positioning its platform as a potential combination therapy to improve outcomes for patients with solid tumors.

Oncology

Technology Platform

Plasmid DNA-based immunotherapy platform designed to deliver the p62/SQSTM1 gene to modulate the tumor microenvironment, reduce inflammation, and enhance anti-tumor immune response.

Funding History

2
Total raised:$15.5M
Series A$15M
Grant$500K

Opportunities

Elenagen's mechanism as a tumor microenvironment modulator presents a significant opportunity for combination therapy with existing standards of care like chemotherapy or checkpoint inhibitors, potentially improving response rates in hard-to-treat solid tumors.
The broad applicability across multiple cancer types could allow for a large target market if clinical efficacy is proven.

Risk Factors

The company faces high clinical risk as its novel, single-asset platform must demonstrate efficacy in larger, controlled trials.
Financial risk is also substantial, as advancing through Phase II and III trials will require significant capital, and the competitive immuno-oncology landscape is crowded with well-resourced players.

Competitive Landscape

CureLab operates in the highly competitive immuno-oncology space, competing against large pharma and biotech firms with approved checkpoint inhibitors, cell therapies, and other modalities. Its differentiation hinges on Elenagen's unique p62/SQSTM1 mechanism aimed at reprogramming the tumor microenvironment, a space also being explored by other companies targeting cancer-associated inflammation and fibrosis.

More companies in Biologics / Biosimilars →More companies in United States →